Clinical Trials Logo

Seizures clinical trials

View clinical trials related to Seizures.

Filter by:

NCT ID: NCT01283256 Completed - Clinical trials for Partial, Generalized and Combined Seizures

A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.

Start date: January 2011
Phase: Phase 4
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of zonisamide in the treatment of adult patients with partial, generalized or combined seizures.

NCT ID: NCT01278173 Completed - Clinical trials for Adult Refractory Complex Partial Seizures

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

Start date: December 2010
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the change in visual fields by means of automated static perimetry and to evaluate the change in retinal structure by means of spectral domain optical coherence tomography (SD-OCT) in adult patients with refractory complex partial seizures (CPS) being treated with vigabatrin (Sabril®)

NCT ID: NCT01262677 Completed - Epilepsies, Partial Clinical Trials

Once-A-Day Pregabalin For Partial Seizures

Start date: February 17, 2011
Phase: Phase 3
Study type: Interventional

Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.

NCT ID: NCT01261416 Completed - Epilepsy Clinical Trials

Pharmacokinetics of Levetiracetam (Keppra) in Neonates

Start date: October 2008
Phase: N/A
Study type: Observational

The primary objective of this study is to determine the pharmacokinetic profile of a loading dose of intravenous levetiracetam, given for clinical reasons, in term and late preterm infants with seizures. Secondary objectives are to evaluate the safety and efficacy of levetiracetam in term and preterm infants with seizures.

NCT ID: NCT01261325 Completed - Epilepsy Clinical Trials

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

BRITE
Start date: December 2010
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.

NCT ID: NCT01239212 Completed - Seizures Clinical Trials

Dosing of Levetiracetam (Keppra) in Neonates

Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg loading dose of intravenous levetiracetam (LEV) in term and late preterm infants with seizures. Secondary objectives are to evaluate the safety and efficacy of a 50 mg/kg loading dose of levetiracetam in term and preterm infants with seizures, and to obtain data on steady state drug levels of levetiracetam in neonates.

NCT ID: NCT01236001 Completed - Seizures Clinical Trials

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Start date: September 2010
Phase: N/A
Study type: Observational

Observational study at the request of the Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV: - type of patient treated with VIMPAT® - VIMPAT® dose - Effect of VIMPAT® on evolution of seizure control - Persistence rate at 6 months in terms of treatment duration - Discontinuation rate - Description of any changes in other epilepsy therapies - Safety and tolerability

NCT ID: NCT01228747 Completed - Epilepsy Clinical Trials

A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Start date: October 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and tolerability of levetiracetam treatment used as adjunctive therapy in Japanese and Chinese epilepsy patients aged ≥16 years and with uncontrolled Generalized Tonic-Clonic seizures despite treatment with 1 or 2 anti-epileptic drugs.

NCT ID: NCT01224457 Completed - Neonatal Seizure Clinical Trials

Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.

Start date: May 2008
Phase: N/A
Study type: Interventional

The pharmacogenomic profiles of drug metabolizing enzymes play an important role in pharmacokinetics (PK) of drugs. Phenobarbital (PB), worldwidely used for neonatal seizure, is a drug that requires careful dose adjustments based on therapeutic drug monitoring. It was reported that phenobarbital (PB) metabolism was affected by CYP2C9 and CYP2C19 polymorphisms in adults. This study aims to evaluate the effects of the CYP2C9 and CYP2C19 genetic polymorphisms on PB PK in infants with neonatal seizure for an optimal dosing strategy.

NCT ID: NCT01179854 Completed - Self Efficacy Clinical Trials

Remegal Different Doses in Patients With Refractory Partial Seizures

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine weather different doses of Remegal are effective,safety and tolerant in Additional Therapy for Patients With Refractory Partial Seizures and pharmacokinetics definition